YSB (09885) released its mid-term performance report, with a net profit attributable to shareholders of 111 million yuan, an increase of 41.9% year-on-year. The company continues to optimize the category structure of its platform to achieve precise expansion on the supply side.

YSB (09885) announced that for the six months ended June 30, 2026, the Group achieved a revenue of 10.283 billion yuan, an increase of 4.5% year-on-year; the profit attributable to owners of the company was 111 million yuan, an increase of 41.9% year-on-year; basic earnings per share were 0.164 yuan. During the reporting period, the Group deepened its collaboration with upstream merchants to build an ecosystem in the pharmaceutical industry, continuously iterating on its cultivation system for quality merchants. While steadily expanding a core strategic ecosystem of partners with monthly sales in the tens of millions of yuan, the Group also continued to incubate small and medium-sized merchants with monthly sales in the hundred-thousand and ten-thousand yuan levels, creating a long-term, stable, compliant, and high-quality upstream supply network. In terms of merchant empowerment, the company employs big data technology as its core driver to implement meticulous category operation strategies, providing upstream merchants with in-depth services such as precise demand profiling, intelligent inventory alerts, and dynamic pricing references, assisting in precise supply and efficient turnover. Relying on the platform's big data demand insight system, the Group accurately captures changes in market demand and continuously optimizes the platform's category structure to achieve precise expansion on the supply side. As of June 30, 2026, the average monthly SKU count on the platform had grown to approximately 4.3 million, a 9% increase compared to the first half of 2025, forming a comprehensive supply matrix covering a full range of categories, including chemical drugs, traditional Chinese medicine (TCM), TCM slices, medical devices, and health supplements. Through refined and differentiated category operations, the platform precisely matches the diverse, scenario-based needs of various procurement entities, continuously consolidating competitive barriers on the supply side. In the TCM slice business sector, the Group adheres to a development path of "standards first, source control, and digital empowerment," continuously deepening the construction of the "Golden Standard" system. During the reporting period, the Group added one cooperative production area each for Tianqi and Goji Vine, expanding the varieties covered by the Golden Standard to 372, with grade standards updated to 1,266, and further extending the range of the digital traceability system covering the entire chain for TCM slices. During the reporting period, the total sales of TCM slices on the platform exceeded 20,000 tons, representing a year-on-year increase of approximately 10%, fully demonstrating the strong empowerment of standardized system construction and digital management capabilities for business growth. Regarding the iteration of the platform's digital infrastructure, the company continues to expand its AI application system, fully enhancing the operational efficiency and decision-making accuracy across the entire industry by deeply coupling large model capabilities with the business middle platform. In terms of profit model, the company primarily generates revenue by charging upstream sellers a predetermined commission rate, with the platform's overall average commission rate remaining stable at 3.3%. At the same time, the Group continues to optimize the platform's subsidy mechanisms and resource allocation systems, balancing platform profitability with ecological activity.